Inflammation contributes to NKX3.1 loss and augments DNA damage but does not alter the DNA damage response via increased SIRT1 expression

Journal of Inflammation

Kemal Sami Korkmaz²  Nursah Ertunc²  Bilge Debelec-Butuner¹ 

[1] Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Ege University, Bornova, Izmir 35100, Turkey;Department of Bioengineering, Cancer Biology Laboratory, Faculty of Engineering, Ege University, Bornova, Izmir, 35100, Turkey

关键词: DNA damage;    Prostate tumor;    Inflammatory microenvironment;    NKX3.1;    ROS;   

Others  :  1134149
DOI  :  10.1186/s12950-015-0057-4

 received in 2014-04-04, accepted in 2015-01-29,  发布年份 2015

【 摘 要 】

The oxidative stress response is a cellular defense mechanism that protects cells from oxidative damage and cancer development. The exact molecular mechanism by which reactive oxygen species (ROS) contribute to DNA damage and increase genome instability in prostate cancer merits further investigation. Here, we aimed to determine the effects of NKX3.1 loss on antioxidant defense in response to acute and chronic inflammation in an in vitro model. Oxidative stress-induced DNA damage resulted in increased H2AX^(S139) phosphorylation (a hallmark of DNA damage), along with the degradation of the androgen receptor (AR), p53 and NKX3.1, upon treatment with conditioned medium (CM) obtained from activated macrophages or H₂O₂. Furthermore, the expression and stability of SIRT1 were increased by CM treatment but not by H₂O₂ treatment, although the level of ATM^(S1981) phosphorylation was not changed compared with controls. Moreover, the deregulated antioxidant response resulted in upregulation of the pro-oxidant QSCN6 and the antioxidant GPX2 and downregulation of the antioxidant GPX3 after CM treatment. Consistently, the intracellular ROS level increased after chronic treatment, leading to a dose-dependent increase in the ability of LNCaP cells to tolerate oxidative damage. These data suggest that the inflammatory microenvironment is a major factor contributing to DNA damage and the deregulation of the oxidative stress response, which may be the underlying cause of the increased genetic heterogeneity during prostate tumor progression.

【 授权许可】

   
2015 Debelec-Butuner et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Guyton KZ, Kensler TW: Oxidative mechanisms in carcinogenesis. Br Med Bull 1993, 49:523-44.
• [2]Khandrika L, Kumar B, Koul S, Maroni P, Koul HK: Oxidative stress in prostate cancer. Cancer Lett 2009, 282:125-36.
• [3]Finkel T: Oxidant signals and oxidative stress. Curr Opin Cell Biol 2003, 15:247-54.
• [4]Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB: Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med 2010, 49:1603-16.
• [5]Schetter AJ, Heegaard NH, Harris CC: Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis 2010, 31:37-49.
• [6]Ushio-Fukai M: Compartmentalization of redox signaling through NADPH oxidase-derived ROS. Antioxid Redox Signal 2009, 11:1289-99.
• [7]Ma Q: Transcriptional responses to oxidative stress: pathological and toxicological implications. Pharmacol Ther 2010, 125:376-93.
• [8]Morgan MJ, Kim YS, Liu ZG: TNFalpha and reactive oxygen species in necrotic cell death. Cell Res 2008, 18:343-9.
• [9]Liu B, Chen Y, St Clair DK: ROS and p53: a versatile partnership. Free Radic Biol Med 2008, 44:1529-35.
• [10]Acharya A, Das I, Chandhok D, Saha T: Redox regulation in cancer: a double-edged sword with therapeutic potential. Oxid Med Cell Longev 2010, 3:23-34.
• [11]Gorospe M, de Cabo R: AsSIRTing the DNA damage response. Trends Cell Biol 2008, 18:77-83.
• [12]Yuan Z, Seto E: A functional link between SIRT1 deacetylase and NBS1 in DNA damage response. Cell Cycle 2007, 6:2869-71.
• [13]Moore RL, Dai Y, Faller DV: Sirtuin 1 (SIRT1) and steroid hormone receptor activity in cancer. J Endocrinol 2012, 213:37-48.
• [14]He WW, Sciavolino PJ, Wing J, Augustus M, Hudson P, Meissner PS, et al.: A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics 1997, 43:69-77.
• [15]Korkmaz KS, Korkmaz CG, Ragnhildstveit E, Kizildag S, Pretlow TG, Saatcioglu F: Full-length cDNA sequence and genomic organization of human NKX3A - alternative forms and regulation by both androgens and estrogens. Gene 2000, 260:25-36.
• [16]Bowen C, Stuart A, Ju JH, Tuan J, Blonder J, Conrads TP, et al.: NKX3.1 homeodomain protein binds to topoisomerase I and enhances its activity. Cancer Res 2007, 67:455-64.
• [17]Markowski MC, Bowen C, Gelmann EP: Inflammatory cytokines induce phosphorylation and ubiquitination of prostate suppressor protein NKX3.1. Cancer Res 2008, 68:6896-901.
• [18]Debelec-Butuner B, Alapinar C, Varisli L, Erbaykent-Tepedelen B, Hamid SM, Gonen-Korkmaz C, et al.: Inflammation-mediated abrogation of androgen signaling: an in vitro model of prostate cell inflammation. Mol Carcinog 2014, 53(2):85-97.
• [19]Khalili M, Mutton LN, Gurel B, Hicks JL, De Marzo AM, Bieberich CJ: Loss of Nkx3.1 expression in bacterial prostatitis: a potential link between inflammation and neoplasia. Am J Pathol 2010, 176:2259-68.
• [20]Minelli A, Bellezza I, Conte C, Culig Z: Oxidative stress-related aging: A role for prostate cancer? Biochim Biophys Acta 2009, 1795:83-91.
• [21]Chua KF, Mostoslavsky R, Lombard DB, Pang WW, Saito S, Franco S, et al.: Mammalian SIRT1 limits replicative life span in response to chronic genotoxic stress. Cell Metab 2005, 2:67-76.
• [22]Mendrysa SM, O’Leary KA, McElwee MK, Michalowski J, Eisenman RN, Powell DA, et al.: Tumor suppression and normal aging in mice with constitutively high p53 activity. Genes Dev 2006, 20:16-21.
• [23]Reichardt JK: GEN: the genomic genetic analysis of androgen-metabolic genes and prostate cancer as a paradigm for the dissection of complex phenotypes. Front Biosci 1999, 4:D596-600.
• [24]Henderson BE, Feigelson HS: Hormonal carcinogenesis. Carcinogenesis 2000, 21:427-33.
• [25]Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC: p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 1993, 53:3369-73.
• [26]Brooks CL, Gu W: p53 regulation by ubiquitin. FEBS Lett 2011, 585:2803-9.
• [27]Yuan H, Su L, Chen WY: The emerging and diverse roles of sirtuins in cancer: a clinical perspective. Onco Targets Ther 2013, 6:1399-416.
• [28]Erbaykent-Tepedelen B, Ozmen B, Varisli L, Gonen-Korkmaz C, Debelec-Butuner B, Muhammed Syed H, et al.: NKX3.1 contributes to S phase entry and regulates DNA damage response (DDR) in prostate cancer cell lines. Biochem Biophys Res Commun 2011, 414:123-8.
• [29]Erbaykent-Tepedelen B, Karamil S, Gonen-Korkmaz C, Korkmaz KS: DNA damage response (DDR) via NKX3.1 expression in prostate cells. J Steroid Biochem Mol Biol 2014, 141:26-36.